Psychiatry and Psychology [F] » Mental Disorders [F03] » Mood Disorders » Depressive Disorder » Depressive Disorder, Major
Description
Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) MeSH
Hierarchy View
Approved Indicated Drugs (24)
Phase 4 Indicated Drugs (57)
Phase 3 Indicated Drugs (33)
Phase 2 Indicated Drugs (102)
Phase 1 Indicated Drugs (32)
Other Experimental Indicated Drugs (42)
Organization Involved with Phase 4 Indications (167)
American Academy of Child Adolescent Psychiatry.
American Foundation for Suicide Prevention
Brain & Behavior Research Foundation
Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
Chinese Academy of Medical Sciences
Chokka Center for Integrative Health
Cognitive Research Corporation
Corning Hospital, Shenzhen City
Erzurum Regional Training & Research Hospital
Hamilton Health Sciences Corporation
Hangzhou Seventh People's Hospital
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Institute for Advanced Medical Research, Alpharetta, GA
Institut National de la Santé Et de la Recherche Médicale, France
Jerusalem Mental Health Center
Lehigh Center for Clinical Research
Michael J. Gill Mental Health Clinic
National Cancer Institute (NCI)
National Center for Research Resources (NCRR)
National Cheng Kung University
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Mental Health (NIMH)
People's Liberation Army of China
Research Foundation for Mental Hygiene, Inc.
Second Military Medical University
Skyland Behavioral Health Associates
Stanley Medical Research Institute
State University of New York, Buffalo
St. Luke's-Roosevelt Hospital Center
the First Specialized Subject Hospital of Harbin
The Massachusetts Mental Health Center
The Medical Research Network, LLC
The University of Texas, Dallas
Organization Involved with Phase 3 Indications (69)
Brain and Cognition Discovery Foundation
Canadian Institutes of Health Research (CIHR)
Case Western Reserve University
Centre Hospitalier Universitaire de Nīmes
Florida Clinical Research Center, LLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Laureate Institute for Brain Research
Midwest Clinical Research Center, Ohio
Mochida Pharmaceutical Company, Ltd.
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Drug Abuse (NIDA)
Pakistan Institute of Living and Learning
Pharmacology Research Institute
Shijiazhuang Pharma Group (CSPC)
Su Zhou YiHua Biotechnology Co. LTD
Organization Involved with Phase 2 Indications (95)
Alexander Mosely Charitable Trust
Artemis Institute for Clinical Research
Badalona Hospital Germans Trias i Pujol
Chengdu University of Traditional Chinese Medicines
Ciusss de L'Est de l'Île de Montréal
Collaborative Neuroscience Network
Columbia Northwest Pharmaceuticals
Comprehensive Psychiatric Care, Norwich CT
CRI-WW Lordes Hospital, Willingboro NJ
Foundation of Hope, North Carolina
Hôpital Maisonneuve Rosemont, Montréal, QC, Canada
Hospital de Sant Pau i Santa Tecla de Tarragona
Katholieke Universiteit Leuven
Maryland Oncology Hematology, PA
MSI Methylation Sciences, Inc.
National Institute of General Medical Sciences (NIGMS)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Northwest Clinical Research Center
Ontario Mental Health Foundation
Psychiatric Medicine Associates, L.L.C.
Reckitt Benckiser Pharmaceutical
Section for Affective Disorders; Northern Stockholm Psychiatry
Organization Involved with Phase 1 Indications (34)
Affective Neuroscience Laboratory
Beijing Winsunny Pharmceutical Co.,Ltd.
Organization Involved with Other Experimental Indications (52)
Abarbanel Mental Health Center
Allama Iqbal Open University Islamabad
Bangabandhu Sheikh Mujib Medical University
Center Abarbanel Mental Health
Chhatrapati Sahuji Maharaj Medical University
Government Medical College, Bhavnagar
Health and Family Welfare Department, Government of Gujarat, India
Instituto de Información e Investigación en Salud Mental A. C.
Hierarchy Tree View
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
